I think it's more of a Welcome Back for Philippe Goix.
Gerald is looking to correct everything from his past and making good with people along the way, shareholders too.
2015
Amarantus Diagnostics Establishes Strategic Advisory Committee
Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies
Dr. Goix commented, "Amarantus Diagnostics has groundbreaking neuro-diagnostic tools which may ultimately be game-changers for the diagnosis of multiple sclerosis (MS) and Alzheimer's disease (AD). I am excited to help the team finalize the commercial plans for the company's MSPrecise® diagnostic for MS which has significant near-term revenue potential. Additionally, the recent data presented at AAIC validating the LymPro Test® raises its potential importance as one of the fundamental diagnostic tools in Alzheimer's drug development for use in biomarker-supported selection of AD patients for clinical trials, and we will be very focused on optimizing IUO marketing and CLIA strategy for LymPro. Both MSPrecise and LymPro are key diagnostic assets with great potential for improving the investigational and commercial paradigms for the diagnoses of MS and AD."
https://www.globenewswire.com/news-release/20...ittee.html
Gerald is looking to correct everything from his past and making good with people along the way, shareholders too.
2015
Amarantus Diagnostics Establishes Strategic Advisory Committee
Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies
Dr. Goix commented, "Amarantus Diagnostics has groundbreaking neuro-diagnostic tools which may ultimately be game-changers for the diagnosis of multiple sclerosis (MS) and Alzheimer's disease (AD). I am excited to help the team finalize the commercial plans for the company's MSPrecise® diagnostic for MS which has significant near-term revenue potential. Additionally, the recent data presented at AAIC validating the LymPro Test® raises its potential importance as one of the fundamental diagnostic tools in Alzheimer's drug development for use in biomarker-supported selection of AD patients for clinical trials, and we will be very focused on optimizing IUO marketing and CLIA strategy for LymPro. Both MSPrecise and LymPro are key diagnostic assets with great potential for improving the investigational and commercial paradigms for the diagnoses of MS and AD."
https://www.globenewswire.com/news-release/20...ittee.html
1
